"Botulinum Toxins, Type A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.
| Descriptor ID |
D019274
|
| MeSH Number(s) |
D08.811.277.656.300.480.153.100 D08.811.277.656.675.374.153.100 D12.776.097.156.100 D23.946.123.179.050
|
| Concept/Terms |
Botulinum Toxins, Type A- Botulinum Toxins, Type A
- Botulinum Neurotoxin A
- Neurotoxin A, Botulinum
- Clostridium botulinum A Toxin
- Clostridium Botulinum Toxin Type A
- Botulinum A Toxin
- Toxin, Botulinum A
- Botulinum Toxin Type A
|
Below are MeSH descriptors whose meaning is more general than "Botulinum Toxins, Type A".
Below are MeSH descriptors whose meaning is more specific than "Botulinum Toxins, Type A".
This graph shows the total number of publications written about "Botulinum Toxins, Type A" by people in this website by year, and whether "Botulinum Toxins, Type A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 3 | 0 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 7 | 0 | 7 |
| 2005 | 7 | 1 | 8 |
| 2006 | 6 | 1 | 7 |
| 2007 | 4 | 1 | 5 |
| 2008 | 3 | 2 | 5 |
| 2009 | 5 | 1 | 6 |
| 2010 | 5 | 0 | 5 |
| 2011 | 11 | 2 | 13 |
| 2012 | 8 | 0 | 8 |
| 2013 | 3 | 1 | 4 |
| 2014 | 7 | 2 | 9 |
| 2015 | 3 | 1 | 4 |
| 2016 | 5 | 2 | 7 |
| 2017 | 5 | 0 | 5 |
| 2018 | 4 | 1 | 5 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 1 | 5 |
| 2021 | 6 | 0 | 6 |
| 2022 | 3 | 0 | 3 |
| 2023 | 8 | 0 | 8 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Botulinum Toxins, Type A" by people in Profiles.
-
Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
-
Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging Study. Plast Reconstr Surg. 2025 Jan 01; 155(1):79-88.
-
Pain Related to Intradetrusor BotulinumtoxinA: A Randomized Clinical Trial. Urogynecology (Phila). 2024 03 01; 30(3):337-344.
-
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
-
Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024 01 15; 456:122810.
-
Comparing botulinum toxin and 4-duct ligation for Sialorrhea in children - A systematic review. Am J Otolaryngol. 2024 Mar-Apr; 45(2):104119.
-
Assessment of efficacy of different botulinum toxin A concentrations in the treatment of androgenetic alopecia assessed by dermoscopy. J Cosmet Dermatol. 2024 Feb; 23(2):417-425.
-
Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32403.
-
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX?) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins (Basel). 2023 05 17; 15(5).
-
Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection. J Pediatr Urol. 2023 12; 19(6):742.e1-742.e8.